Vaxxa First Quarter 2025 Earnings: kr0.016 loss per share (vs kr0.012 profit in 1Q 2024)
Vaxxa (NGM:VAXXA) First Quarter 2025 Results
Key Financial Results
- Revenue: kr12.9m (down 38% from 1Q 2024).
- Net loss: kr682.0k (down by 319% from kr312.0k profit in 1Q 2024).
- kr0.016 loss per share (down from kr0.012 profit in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Vaxxa shares are down 7.8% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 5 warning signs for Vaxxa (4 are significant!) that you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Vaxxa might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.